and Expression Therapeutics
are collaborating to develop novel cell and protein therapies for hemophilia A. Expression Therapeutics high-expression factor VIII technology will be combined with Lentigen's protein expression and gene transfer capabilities.
The companies will develop two types of treatments: a chimeric factor VIII protein for direct injection and a cell therapy that may permanently correct the disorder. “Factor VIII is a difficult protein to manufacture, but Lentigen's protein expression technology will permit the production of a novel human factor VIII protein at levels highly favorable for commercialization,” notes Boro Dropulic, president and CSO of Lentigen.
“Secondly, Expression Therapeutics' proprietary factor VIII will be used in a novel stem cell therapy for hemophilia A that aims to restore the clotting capability of patients suffering from this debilitating disease.”